Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 10, 2015, Pages 2870-2880

  Malet, Isabelle ^a   Thierry, Eloise ^b   Wirden, Marc ^a   Lebourgeois, Samuel ^b   Subra, Frédéric ^b   Katlama, Christine ^a   Deprez, Eric ^b   Calvez, Vincent ^a   Marcelin, Anne Geneviève ^a   Delelis, Olivier ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Ecole Normale Superieure de Cachan   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; INTEGRASE; RALTEGRAVIR; VIRUS DNA; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; EC50; ENZYME ACTIVITY; FEMALE; G140S MUTATION; GENE MUTATION; HUMAN; HUMAN CELL; MALE; N155H MUTATION; Q148H MUTATION; SITE DIRECTED MUTAGENESIS; VIRUS DNA CELL DNA INTERACTION; VIRUS INFECTIVITY; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; CELL LINE; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; PROVIRUS; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL LINE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MUTATION; PROVIRUSES; RALTEGRAVIR POTASSIUM; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; VIRAL LOAD; VIRUS REPLICATION;

EID: 84943778107     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv197     Document Type: Article

References (39)

1. Delelis O, Carayon K, Saib A, et al. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology 2008; 5: 114.
2. Nguyen BY, Isaacs RD, Teppler H, et al. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann NY Acad Sci 2011; 1222: 83-9.
3. Wills T, Vega V. Elvitegravir: a once-daily inhibitor of HIV-1 integrase. Expert Opin Investig Drugs 2012; 21: 395-401.
4. Krishnan L, Li X, Naraharisetty HL, et al. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci USA 2010; 107: 15910-5.
5. Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol 2012; 10: 279-90.
6. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287: 646-50.
7. Serrao E, Odde S, Ramkumar K, et al. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009; 6: 25.
8. Malet I, Delelis O, Valantin MA, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008; 52: 1351-8.
9. Malet I, Delelis O, Valantin MA, et al. Biochemical characterizations of the effect of mutations selected in HIV-1 integrase gene associated with failure to raltegravir (MK-0518). Antivir Ther 2007; 12: S9-S.
10. Delelis O, Thierry S, Subra F, et al. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother 2010; 54: 491-501.
11. Goethals O, Clayton R, Van Ginderen M, et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008; 82: 10366-74.
12. Garrido C, Villacian J, Zahonero N, et al. Broad phenotypic crossresistance to elvitegravir in HIV-infected patients failing on raltegravircontaining regimens. Antimicrob Agents Chemother 2012; 56: 2873-8.
13. Bar-Magen T, Sloan RD, Donahue DA, et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010; 84: 9210-6.
14. Goethals O, Van Ginderen M, Vos A, et al. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. Antiviral Res 2011; 91: 167-76.
15. Goethals O, Vos A, Van Ginderen M, et al. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to firstgeneration integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology 2010; 402: 338-46.
16. Hare S, Smith SJ, Metifiot M, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 2011; 80: 565-72.
17. Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials 2013; 14: 192-203.
18. Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS 2013; 8: 565-71.
19. Yoshinaga T, Kobayashi M, Seki T, et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother 2015; 59: 397-406.
20. Hightower KE, Wang R, Deanda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011; 55: 4552-9.
21. Canducci F, Ceresola ER, Saita D, et al. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. J Antimicrob Chemother 2013; 68: 2525-32.
22. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55: 813-21.
23. Mesplede T, Quashie PK, Zanichelli V, et al. Integrase strand transfer inhibitors in the management of HIV-positive individuals. Ann Med 2014; 46: 123-9.
24. Quashie PK, Sloan RD, Wainberg MA. Novel therapeutic strategies targeting HIV integrase. BMC Med 2012; 10: 34.
25. Hardy I, Brenner B, Quashie P, et al. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother 2015; 70: 405-11.
26. Quashie PK, Mesplede T, Han YS, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012; 86: 2696-705.
27. Mesplede T, Quashie PK, Osman N, et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 2013; 10: 22.
28. Munir S, Thierry E, Malet I, et al. G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance. J Antimicrob Chemother 2015; 70: 739-49.
29. Malet I, Gimferrer Arriaga L, Artese A, et al. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemother 2014; 69: 2118-22.
30. Danion F, Belissa E, Peytavin G, et al. Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Qmutated virus in the integrase region. J Antimicrob Chemother 2015; 70: 1921-3.
31. Munir S, Thierry S, Subra F, et al. Quantitative analysis of the timecourse of viral DNA forms during the HIV-1 life cycle. Retrovirology 2013; 10: 87.
32. Delelis O, Parissi V, Leh H, et al. Efficient and specific internal cleavage of a retroviral palindromic DNA sequence by tetrameric HIV-1 integrase. PLoS One 2007; 2: e608.
33. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007; 12: 563-70.
34. Delelis O, Malet I, Na L, et al. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res 2009; 37: 1193-201.
35. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. New Engl J Med 2008; 359: 355-65.
36. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82: 764-74.
37. Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviralexperienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014; 210: 354-62.
38. Malet I, Delelis O, Soulie C, et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 2009; 63: 795-804.
39. Seki T, Suyama-Kagitani A, Kawauchi-Miki S, et al. Effects of raltegraviror elvitegravir-resistant signature mutations on the barrier to dolutegravir resistance in vitro. Antimicrob Agents Chemother 2015; 59: 2596-606.